![Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects. PLOS ONE, 2024](https://www.reactionbiology.com/wp-content/uploads/2024/08/Bakri2024-e1724552159510-1027x675.png)
![Vorolanib, sunitinib, and axitinib: A comparative study of vascular endothelial growth factor receptor inhibitors and their anti-angiogenic effects. PLOS ONE, 2024](https://www.reactionbiology.com/wp-content/uploads/2024/08/Bakri2024-e1724552159510-1027x675.png)
![Cellular Angiogenesis Assay](https://www.reactionbiology.com/wp-content/uploads/2023/07/Angiogenesis.png)
Cellular Angiogenesis Assay
![Spheroid-based human endothelial cell microvessel formation in vivo. Nature Protocols, 2009](https://www.reactionbiology.com/wp-content/uploads/2023/07/Spheroid-Nature_Publication_thumbnail.png)
Spheroid-based human endothelial cell microvessel formation in vivo. Nature Protocols, 2009
![Markedly divergent effects of Ouabain on a Temozolomide‑resistant (T98G) vs. a Temozolomide‑sensitive (LN229) Glioblastoma cell line. Discover Oncology, 2023](https://www.reactionbiology.com/wp-content/uploads/2023/07/2023_Weidemann_Migration-Ouabain_DiscoverOncology.png)
Markedly divergent effects of Ouabain on a Temozolomide‑resistant (T98G) vs. a Temozolomide‑sensitive (LN229) Glioblastoma cell line. Discover Oncology, 2023
![Endothelial cell spheroids as a versatile tool to study angiogenesis in vitro. The FASEB Journal, 2015](https://www.reactionbiology.com/wp-content/uploads/2023/07/2015_cell_angiogenesis_spheroids_FASEB_thumb.png)